UNEMON1's  Instablog

Send Message
"Risk comes from not knowing what you're doing" Warren Buffett I look and sift the world for such misplaced bets. When I occasionally find one, I first exploit it for profit. Then, I write about it for anyone else interested in such ideas. Twitter: @unemon1 Scribd:... More
  • Do You Think Organovo Has NO-Competitors? Think Again About It! It Is An Overcrowded Market The 3D Bioprinting Space 3 comments
    Feb 5, 2014 1:34 PM | about stocks: ONVO

    - Don't follow me, I could be wrong !! -

    As a potential ORGANOVO investors you are probably already aware of my opinion about this Company.

    Various Bloggers and Posters (such as Motley) highlight the uniqueness of 3D biopritings and its future potential as the main reason for justifying ORGANOVO unbelievable high Valuation.

    HERE IS SOME NEWS FOR YOU: 3D bioprinting is an overcrowded Market.

    IMO, the major difference between ONVO and the Other Companies consists in ONVO being a Listed Company and having therefore gained most of the media attention! (Let's welcome the wolves of Japan)

    Look at a list of Commercial Developers of In Vitro Models and Applications. As you can see, Organovo is just one of many (37 companies).

    For a higher quality view ... I uploaded the printed PDF page here:


    The article was made abailable online on October 29, 2012 and will be pulished in Biotechnology Advances (a review journal which considers all aspects of the multidisciplinary fiels. The scope includes biotechnology principles and applications in ... )


    Zhaohui Li, Zhanfeng Cui

    Institute of Biomedical Engineering, Department of Engineering Science, Oxford University, Oxford, UK

    This article also offers a nice overview on the 3D cultures preprinting space. You can purchase it at the following link:


    So... are you ready to pay ... ... USD 700m for the privilege of being an investors in a "publicly traded Company" ... with no proven track record ... with insignificant revenue ... and ... with a history of failing to meet generated expectations*? ... (Please see my notes on Valuations issues /link below/)

    Sorry ... but I would rather pass! Actually ... I am shorting this madness!

    I would not be surprised to see some other "PRICE SUPPORTING" PRs or Comments coming out in the coming weeks. All that will do ... is giving me an opportunity to gain more short exposure in a Company which I believe to be highly overvalued and misunderstood.

    A very good article on ONVO (November 2013):


    My View on Organovo Over Valuation


    My thoughts on Organovo + Pfizer Partnership


    *pls, note that in the S-1 filings ... the core business activity cited was the sale of their 3D printers for commercial applications. Well, the way I see it ... it did not work out ... and so a change in strategy occurred. Now they are branding themselves as a "SERVICE PROVIDER" ... providing big Pharma Companies with 3D tissues models... for their (drug) testing. Apparently, ppl haven't yet realized how over-crowded such a market is. I bet my $$$ ... ONVO will once again fail to meet the gigantic expectations investors have!

    Disclosure: I am short ONVO.

    Stocks: ONVO
Back To UNEMON1's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • scothania
    , contributor
    Comment (1) | Send Message
    None have the Backing!!! ONVO is on top. This is why????? You don't' think others have looked into their competitors?
    Who else has the liver tech development as far along as them? Please let me know when you find out.
    5 Feb 2014, 09:01 PM Reply Like
    , contributor
    Comments (421) | Send Message
    Author’s reply » Sure,


    Actually ... Insphero AG is working with PFIZER and ROCHE .... on the 3D liver tissues! ... They announced the results in late 2013 and were top-in Class.


    If gullible retails investors had looked into ONVO's competitors ... they would have figured out how incredibly overvalued Oranovo was ... and never have bought at a price > than 4$


    Read this ... to see ... that Pfizer is now working with Inpshero AG on liver tissues!


    What did happen to the Phartnership with Organovo? Why is Pfizer now working with INSPHERO? ... good luck ...
    5 Feb 2014, 09:19 PM Reply Like
  • Daniel McMillen
    , contributor
    Comments (6) | Send Message
    Looks to me like Pfizer is being smart and is poking its head into potential companies that will emerge into this emerging industry. Loved the article, however I believe that this specific industry still has a long road ahead and it is a complicated guess to favor either side (although this is a very well thought out argument with some very interesting points that have to be made for speculations sake). Keep up the good work!!!
    6 Feb 2014, 10:32 PM Reply Like
Full index of posts »
Latest Followers


  • $PHMD: A True Turnaround Story? Regaining Access To The Japan Market? http://seekingalpha.com/p/2aouk
    Mar 26, 2015
  • $DK Real question GeoInvesting should ask is: "why had DELEK Hungary liquidated 32.359m DK shares over the past 2.5 years?"
    Mar 5, 2015
  • $ATHX up to 205m USD in milestone payments + 2digit royailty for just the JP market on 1 indication. $ATHX currently at 200m mcap.
    Mar 2, 2015
More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.